PHA-739358 for the Treatment of Multiple Myeloma
- Registration Number
- NCT00872300
- Lead Sponsor
- Nerviano Medical Sciences
- Brief Summary
The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 7
Inclusion Criteria
- active multiple myeloma progressing after at least 2 prior lines of treatment
- measurable disease
- t(4;14) translocation
- life expectancy of at least 3 months
Exclusion Criteria
- uncontrolled hypertension
- myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.
- pregnancy or breast feeding
- active infections, including HIV
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 PHA-739358 -
- Primary Outcome Measures
Name Time Method Response Rate according to International Myeloma Working Group uniform response criteria for multiple myeloma. At end of each cycle
- Secondary Outcome Measures
Name Time Method Overall safety profile All cycles
Trial Locations
- Locations (4)
Hôpital Huriez, Centre Hospitalier Régional Universitaire de Lille
🇫🇷Lille, France
University Hospital Hôtel-Dieu
🇫🇷Nantes, France
The Robert H Lurie Comprehensive Cancer Center, Northwestern University
🇺🇸Chicago, Illinois, United States
MAYO Clinic
🇺🇸Scottsdale, Arizona, United States